We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+1.76%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$128M
AUM Growth
-$101M
Cap. Flow
-$100M
Cap. Flow %
-78.42%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
3
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$42.5M
2
PLRX icon
Pliant Therapeutics
PLRX
+$41.8M
3
FULC icon
Fulcrum Therapeutics
FULC
+$13M
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$2.69M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$42.1B
$38.2M 29.95%
1,604,130
-2,000,000
-55% -$42.5M
PLRX icon
2
Pliant Therapeutics
PLRX
$65M
$35.6M 27.86%
1,839,160
-2,000,000
-52% -$41.8M
VYGR icon
3
Voyager Therapeutics
VYGR
$189M
$33.1M 25.95%
5,428,933
– –
FULC icon
4
Fulcrum Therapeutics
FULC
$288M
$14.3M 11.2%
1,962,202
-2,000,000
-50% -$13M
DBTX
5
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$6.44M 5.04%
3,139,685
– –
JNCE
6
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-1,148,780
Closed -$2.69M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q4 2022 Portfolio in Review

As of Q4 2022, TRV GP III held 6 positions worth $128M, down 44% from $229M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III withdrew a net $100M in Q4 2022, closing 1 position and reducing 3 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $2.69M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q4 2022 reduction was Revolution Medicines, cutting an estimated $42.5M.
  • TRV GP III fully exited Jounce Therapeutics, Inc. Common Stock in Q4 2022, selling an estimated $2.69M.
  • TRV GP III's ten largest holdings make up 100% of its $128M portfolio in Q4 2022.
  • TRV GP III opened 0 new positions and closed 1 in Q4 2022.
  • TRV GP III's portfolio value fell 44% quarter-over-quarter to $128M.

Based on TRV GP III's 13F filing for Q4 2022, filed 14 Feb 2023.